Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200432 · ClinicalTrials.gov registry record · NA
Patient Experience Recommender System for Persuasive Communication Tailoring
A NA study, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- NA
- Development phase
- 972
- Enrollment target
NCT02200432: Completed NA study, sponsored by University of Massachusetts, Worcester.
NCT02200432 is a NA study that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 972 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02200432, a NA study, has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- NA
- Development phase
- 972 participants
- Enrollment target
Study Summary
The purpose of this study is to maximize patient perspective and effectively support lifestyle choices, investigators will develop the "Patient Experience Recommender System for Persuasive Communication Tailoring." PERSPeCT is a computer system that will assess adult smokers' perspective, to understand the patient's preferences for smoking cessation health messages, and provide personalized, persuasive health communication that is useful to the individual patient in making positive health behavior changes such as smoking cessation.
Primary Outcome
To evaluate the success of PERSPeCT in motivating smokers, we will conduct a pilot randomized trial. We hypothesize that the messages delivered by PERSPeCT will be more influential in encouraging a quit attempt, as compared with messages selected to be delivered by our current rule-based computer tailored messaging system.
Interventions
- OTHER PERSPeCT Recommender System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 972 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT02200432 record still lists
NCT02200432 is an interventional study that assigns participants to a tested intervention. The registered 972 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which PERSPeCT Recommender System is the first listed.
NCT02200432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02200432 about?
NCT02200432 is a clinical study titled "Patient Experience Recommender System for Persuasive Communication Tailoring". The purpose of this study is to maximize patient perspective and effectively support lifestyle choices, investigators will develop the "Patient Experience Recommender System for Persuasive Communication Tailoring." PERSPeCT is a computer system that will assess adult smokers' perspective, to underst...
What is the current status of trial NCT02200432?
This trial is currently completed. It is a NA study. The enrollment target is 972 participants. The study started on 2014-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02200432?
The interventions under investigation include: PERSPeCT Recommender System (OTHER).
Who is sponsoring clinical trial NCT02200432?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02200432's enrollment target sits among peer trials
972 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06948422 · 974 participants · Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- NCT05354141 · 970 participants · Phase 3
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
- NCT05600777 · 975 participants · Phase 3
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- NCT06541704 · 975 participants · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia